Multiple myeloma is a rare blood cancer of the plasma cells in bone marrow -- the soft, spongy interior of bone where all blood cells are produced.

Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and ...

By MELINDA J. OVERSTREET for Glasgow News 1 In September 2023, he had been fighting a cold for weeks and weeks. His immune ...

Multiple myeloma begins when abnormal cells multiply and grow uncontrollably in a person’s bone marrow, crowding out healthy ...

Celltrion USA launches 2 denosumab biosimilars, Stoboclo and Osenvelt, enhancing treatment options for osteoporosis and ...

Multiple myeloma bone lesions occur when cancerous cells cause the bones to form weak spots, which can lead to breaks. Learn more about lesions and pain.

Fatigue, bone pain, and frequent infections can all be signs of the blood cancer multiple myeloma, which often has no early distinctive symptoms.

Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® ...

Diagnosis also required -- and still does -- the presence of at least 10% infiltration of clonal plasma cells on bone marrow examination or a biopsy-proven bony or extramedullary plasmacytoma ...

Fresenius Kabi’s fifth and sixth biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) have launched in the ...